NCT03529331 is a Phase 4 clinical trial of Morphine Sulfate Immediate Release in Pain, sponsored by Antonios Likourezos.

Who is sponsoring NCT03529331?

NCT03529331 is sponsored by Antonios Likourezos.

What drugs are being tested in NCT03529331?

Interventions in NCT03529331: Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen.

Is NCT03529331 still recruiting?

NCT03529331 is currently withdrawn. Last updated 23 April 2019.

Last reviewed 2019-04-23 · How we verify

NCT03529331

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED

Withdrawn Phase 4 Last updated 23 April 2019

What this trial tests

Phase 4 trial testing Morphine Sulfate Immediate Release in Pain. Withdrawn.

Timeline

1 September 2019

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Antonios Likourezos
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	quadruple
Primary purpose	treatment
Start date	1 September 2019
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across United States

Drugs / interventions tested

Morphine Sulfate Immediate Release — full drug profile →
Oxycodone/Acetaminophen
Hydrocodone/Acetaminophen

Conditions studied

Pain — all drugs for Pain →

Sponsor

Antonios Likourezos — full company profile →

Who can join

Adults 18 to 120, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized, clinical trial comparing recurrent use of Morphine Sulfate Immediate Release (MSIR), Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at discharge from the emergency department for opioid-naive adult patients presenting with moderate-to-severe pain. At discharge, patients will be randomized to receive either 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days, 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days, or 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days. At 1 month, 3 months, and 6 months patients' prescription's history will be accessed by using the DoctorFirst Drug Database to determine the recurrent use that will serve as a surrogate marker of likeability and abuse liability of each prescribed opioid.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

NCT07533409 — Tactile and Pain Sensory Thresholds and Hand Grip Strength · recruiting
NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
NCT07290205 — Remimazolam NeuroImaging · EARLY_PHASE1 · recruiting
NCT07487610 — Relationship Between Neuropathic Pain and Geriatric Assessment Parameters in Patients Aged 80 Years and Older · recruiting
NCT07454993 — The Effect of Music During Colonoscopy · NA · recruiting

Other Antonios Likourezos trials

Trials by the same sponsor.

NCT06685107 — Virtual Reality and Standard Care vs. Standard Care Alone for Acute MSK Pain in Geriatric ED Patients · NA · recruiting
NCT06473597 — A Comparison of Nurtec ODT to Maxalt MLT-ODT in Adult ED Patients With Migraine Headache · Phase 4 · recruiting
NCT06364540 — Nebulized Ketamine to Nebulized Fentanyl for Treating Acute Painful Conditions in the ED · Phase 4 · recruiting
NCT05227937 — Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study · recruiting
NCT05143489 — The Effect of Pretreatment With Intravenous Lidocaine for Intravenous Contrast: · Phase 4 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03529331 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Antonios Likourezos
Last refreshed: 23 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03529331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing